19 Mid Cap Stocks Just Made New 52-Week Highs
A cluster of biotechnology names hits new highs, but the underlying business stories diverge sharply.
Bio-Techne (TECH) is up 35.1% over the last month, leading a list of 19 Mid Cap stocks from the Russell 3000 at new 52-week highs. These gains stand out when the S&P 500 has returned just +1.7% over the same period.
With Biotechnology accounting for 5 of the 19 names, the central question is whether this strength in price is matched by strength in the underlying business. Here are the names making the list on Thursday, July 9.
The Full List, Largest First
The table below shows the 10 largest of the 19 names, sorted by market capitalization, with returns over four windows:
| Tickers | Market Cap |
1D % Chg |
1W % Chg |
1M % Chg |
1Y % Chg |
|---|---|---|---|---|---|
| NTRS | $33.9 Bil | 1.6% | 4.1% | 8.1% | 48.5% |
| ROIV | $26.4 Bil | 2.0% | 5.1% | 29.2% | 239.0% |
| OKTA | $26.2 Bil | 1.4% | 6.0% | 27.4% | 52.6% |
| FFIV | $24.4 Bil | 2.7% | 1.4% | 8.6% | 42.3% |
| INCY | $23.6 Bil | 1.1% | 4.1% | 17.8% | 75.1% |
| EXPD | $22.8 Bil | 3.8% | 2.3% | 4.4% | 47.0% |
| NBIX | $18.1 Bil | 1.3% | 7.6% | 10.7% | 40.2% |
| BBIO | $17.6 Bil | 15.1% | 21.0% | 33.8% | 108.8% |
| LAMR | $16.4 Bil | 1.3% | 3.6% | 9.5% | 37.9% |
| TIGO | $15.8 Bil | 0.4% | 5.2% | 13.8% | 178.7% |
Are these businesses earning their new highs?
Not always. Consider Roivant Sciences (ROIV), the second-largest company on the list. Its stock has gained 29.2% over the last month, yet its revenue declined 71.6% over the last twelve months and its operating margin is -15560.6%.
In contrast, fellow Biotechnology name Incyte (INCY) is also at a high, but its revenue grew 21.5% over the last twelve months. The company generated a 27.1% operating margin and trades at 16.5 times trailing earnings.
So is a new high a signal to buy or to be cautious?
A 52-week-high list is a map of what the market is rewarding, and strength often persists. But a high price is an observation, not a verdict. The disciplined step is to ask if the business fundamentals justify the new valuation.
The list is where the work begins, not where it ends.
A new high tells you what the market already believes. The harder question is which of these runs management itself is underwriting. Our Guidance Momentum screen tracks exactly that: stocks where the company raised its own forward numbers.
One more pattern worth noticing: 8 of the 19 names are Health Care stocks. When a whole group is making new highs together, a biotech ETF like IBB is one way to own the group’s strength without betting on which single name leads it from here.
Strength Is A Clue. It Is Not A Plan
A stock at its 52-week high has momentum on its side, and momentum is a real force. It is also the most crowded signal in the market, and the difference between a run that lasts and one that tops is always the business underneath.
Checking that business, across thousands of names, is how the Trefis High Quality (HQ) Portfolio is assembled: roughly 30 companies that pass the quality screens, rebalanced on rules. It has a track record of outpacing a benchmark that combines all major indices – the S&P 500, S&P Mid-cap, and Russell 2000. Let the highs point; let the discipline decide.